Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 16/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21618334 | 0.89 | ATF4 (0.60) | ATF4KMT2AUSP2MEN1NPC1 | |
| SCHEMBL23773253 | 0.86 | ATF4 (0.56) | ATF4KMT2AMEN1 | |
| SCHEMBL20974135 | 0.83 | ATF4 (0.74) | ATF4 | |
| SCHEMBL30024698 | 0.82 | ATF4 (0.79) | ATF4 | |
| SCHEMBL19569507 | 0.82 | ATF4 (0.79) | ATF4 | |
| SCHEMBL19569575 | 0.82 | ATF4 (0.64) | ATF4 | |
| SCHEMBL30024822 | 0.82 | ATF4 (0.64) | ATF4 | |
| SCHEMBL23773229 | 0.82 | ATF4 (0.54) | ATF4 | |
| SCHEMBL23773390 | 0.82 | ATF4 (0.58) | ATF4 | |
| SCHEMBL20722080 | 0.81 | ATF4 (0.68) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | claimed |
| EP-3820843-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-05-19 | — | — | EP | claimed |
| WO-2020012339-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-01-16 | — | — | WO | claimed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3820843-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020012339-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | ATF4, EIF2AK4, ATF1 | ATF4 1/4885SLC2A1 701/4885KMT2A 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.